|MDACC Study No:||2011-0513 (clinicaltrials.gov NCT No: NCT01351935)|
|Title:||Phase 1b, Escalating Dose Study of AVL-292, a Bruton’s Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma,|
Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia
|Principal Investigator:||Jan A. Burger|
|Study Description:||The goal of this clinical research study is to find the recommended dose of |
AVL-292 that researchers think may work best in the treatment of patients with
relapsed or refractory B-NHL, CLL, or WM. The safety of this drug will also be
AVL-292 is designed to block the function of an enzyme that helps B cells
work. B cells are white blood cells that are the targets of B-NHL, CLL, and
WM. By blocking the function of this enzyme, AVL-292 may or may not cause the
tumor to shrink.
This is an early study using AVL-292 in humans.